Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

UBS bullish on Biohaven stock with new Buy rating and $59 target

EditorRachael Rajan
Published 06/02/2024, 16:22
© Reuters.
BHVN
-

On Tuesday, UBS initiated coverage on Biohaven Pharmaceutical Holding Company (NYSE:BHVN), assigning a Buy rating to the stock along with a price target of $59.00. The firm's stance is based on Biohaven's clinical-stage biotech profile, which includes a wide range of pipeline opportunities across various therapy areas.

"We are bullish on the pipeline that represents a diverse set of innovative programs," said a UBS analyst.

According to the analyst, the diverse set of innovative programs within Biohaven's pipeline are a strong point for the company. The firm is particularly optimistic about the upcoming Phase 1 data for BHV-1300, a degrader, expected in the first quarter, and the Phase 3 Spinal muscular atrophy (SMA) read-out anticipated in the second half of 2024.

The analyst pointed out that the current stock valuation of Biohaven reflects a revenue projection of $1.1 billion by 2030. However, UBS's base case projects that the company's revenues could reach $1.5 billion by that time. This projection underscores the firm's confidence in Biohaven's growth potential and its pipeline's ability to deliver positive outcomes.

InvestingPro Insights

In light of UBS's optimistic outlook for Biohaven Pharmaceutical Holding Company (NYSE:BHVN), several metrics from InvestingPro provide additional context to their analysis. The market capitalization of Biohaven stands at $3.78 billion, reflecting the company's substantial size within the biotech sector. Despite not being profitable over the last twelve months, as indicated by a negative P/E ratio of -5.11, Biohaven has shown significant returns, with a 160.84% one-year price total return.

InvestingPro Tips reveal a mixed financial health picture. Biohaven has experienced a significant return over the last week, with a 7.65% increase in its stock price, and a large price uptick over the last six months, boasting a 139.51% return. This aligns with the UBS analyst's positive sentiment about the company's potential. On the other hand, Biohaven suffers from weak gross profit margins and analysts do not anticipate the company will be profitable this year, which may warrant cautious optimism among investors.

The company's financial resilience is evident as its liquid assets exceed short-term obligations, suggesting a stable financial footing for its ongoing clinical trials and pipeline development. Additionally, Biohaven operates with a moderate level of debt, which could provide flexibility in funding its operations. For investors seeking further insights, there are 14 additional InvestingPro Tips available, which could help in making a more informed decision on Biohaven's stock. To access these tips, consider using the coupon code "SFY24" to get an additional 10% off a 2-year InvestingPro+ subscription, or "SFY241" to get an additional 10% off a 1-year InvestingPro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.